Skip To Content

Congresses Diabetes

ISPAD Montreal

2025

Filters Content Type
Clear All

Presented Materials

Poster

INHALE-1: A 26-week Primary Treatment with 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza® vs Rapid-Acting Analogue Insulin in Pediatric Subjects with Diabetes

Michael Haller, presented by Jamie Wood

To locate the MSL for your region, please email [email protected], and include your name, title, address, and therapeutic area/product of interest.